Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expirations, FDA safety updates, and global manufacturing data make Organon & Co鈥檚 disclosures dense. Finding how a contraceptive brand鈥檚 revenue shifted, or whether a biosimilar launch triggered new litigation, means combing through hundreds of pages. If you have ever asked, 鈥淗ow do I read Organon & Co SEC filings explained simply?鈥� this page is for you.
Stock Titan鈥檚 AI turns every Organon & Co annual report 10-K simplified, Organon & Co quarterly earnings report 10-Q filing, and Organon & Co 8-K material events explained into plain-English summaries. Need real-time alerts? We capture Organon & Co Form 4 insider transactions real-time the moment they hit EDGAR, spotlighting executive stock moves before market close. Our platform links each filing type to questions investors actually ask:
- 10-K / 10-Q 鈥� segment sales for women鈥檚 health, biosimilar revenue trends, and R&D pipeline costs, plus AI-driven Organon & Co earnings report filing analysis.
- 8-K 鈥� drug-approval milestones and manufacturing notices, with concise context so understanding Organon & Co SEC documents with AI takes minutes, not hours.
- Form 4 鈥� monitor Organon & Co insider trading Form 4 transactions and flag unusual buying in advance of biosimilar launches.
- DEF 14A 鈥� review the Organon & Co proxy statement executive compensation for insight into incentive alignment.
Whether you鈥檙e tracking patent-cliff risk or confirming Organon & Co executive stock transactions Form 4, our expert analysis and AI-powered summaries let you focus on decisions, not document mining. All filings, all in one place鈥攗pdated as soon as Organon presses 鈥渟ubmit.鈥�
iShares Bitcoin Trust ETF (ticker IBIT) has filed Pre-Effective Amendment No. 2 to its Post-Effective Amendment No. 2, converting the prior Form S-1 registration to a shelf Form S-3 and updating disclosure through 27 June 2025. The Delaware statutory trust鈥攕ponsored by iShares Delaware Trust Sponsor LLC, an indirect subsidiary of BlackRock鈥攊ssues shares that track the price performance of bitcoin before expenses.
Scale and capital structure. 鈥� The Trust鈥檚 net asset value (NAV) was $74.20 billion with a per-share NAV of $60.70. 鈥� Shares are listed on NASDAQ under the symbol IBIT and trade independently of NAV. 鈥� Creation/redemption occurs only in baskets of 40,000 shares, valued at either bitcoin or cash; as of 25 June 2025 one basket equated to 22.72 BTC (鈮� $2.45 million).
Expense profile. The Trust鈥檚 single recurring cost is the Sponsor鈥檚 Fee of 0.25% (accrued daily, paid quarterly), one of the lowest expense ratios among crypto-linked exchange-traded products. The Sponsor also absorbs a broad range of routine operating expenses鈥攊ncluding trustee, administration, audit, listing and registration fees鈥攗p to $500 k in annual legal costs, and all organisational costs.
Service framework. 鈥� BlackRock Fund Advisors acts as Trustee. 鈥� Coinbase Custody Trust Co. is the primary bitcoin custodian; Anchorage Digital Bank N.A. is named as an alternative. 鈥� The Bank of New York Mellon serves as cash custodian and administrator. 鈥� Prime Execution Agent services are provided by Coinbase Inc.; Cumberland DRW, Flow Traders, JSCT and Virtu are approved bitcoin trading counterparties. 鈥� Twelve Authorised Participants can create/redeem in cash; four can transact in-kind.
Key updates. 1) Potential adoption of an in-kind creation/redemption process alongside existing cash flows. 2) Inclusion of audited financial data through the 5 March 2025 annual report. 3) Expanded risk disclosures addressing market volatility, regulatory uncertainty and executive-order developments around a prospective U.S. strategic bitcoin reserve.
Risk highlights. The prospectus devotes extensive space to bitcoin price volatility (one-year trailing volatility 鈮� 65%), custody security, fork/air-drop treatment (the Trust permanently abandons ancillary coins), regulatory classification risks under SEC, CFTC, FinCEN and state regimes, and potential divergence between share price and NAV if arbitrage mechanisms are impaired.
Dissolution triggers include delisting, regulatory orders, loss of critical service providers, or failure to qualify as a grantor trust. Upon dissolution, remaining bitcoin would be liquidated and net proceeds distributed via DTC.
Overall, the filing positions IBIT as a large-scale, low-fee vehicle for institutional-grade access to spot bitcoin exposure, while emphasizing the material risks inherent in digital-asset markets.
FAQ
What is the current stock price of ORGANON & CO (OGN)?
What is the market cap of ORGANON & CO (OGN)?
What are the primary business segments of Organon & Co?
What markets does Organon & Co operate in?
How does the company generate its revenue?
What distinguishes Organon & Co in the pharmaceutical industry?
Can you explain the historical background of Organon & Co?
How is Organon & Co positioned against competitors?
What are the key aspects of its operational strategy?
